Tauopathies describe a group of neurodegenerative diseases in which the protein tau, encoded by the gene *MAPT*, is aberrantly misfolded, leading to tau aggregation, neural dysfunction, and cell death (Spillantini and Goedert, 2013). In Alzheimer\'s disease (AD), tau forms the characteristic intracellular neurofibrillary tangles (NFTs), which are thought to be the major cause of neurodegeneration (Bloom, 2014). In other tauopathies, including frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17T), corticobasal degeneration and progressive supranuclear palsy, there are specific forms of tau aggregates and filaments without any amyloid pathology, demonstrating tau\'s potent disease-causing potential (Spillantini and Goedert, 2013). Tau is a microtubule (MT) binding protein, which becomes abnormally hyperphosphorylated on several residues prior/during the process of aggregation, thereby causing loss of its MT binding activity (Mandelkow and Mandelkow, 2012). The importance of tau as a single cause of disease is reinforced by the identification of numerous (\> 55) mutations in autosomal-dominant forms of familial tauopathies, many of which occur in the MT binding domain. Indeed, more and more diseases are being uncovered in which aberrant phosphorylation and folding of tau is implicated, not least in Huntington\'s disease (HD), while *MAPT* is a genetic risk factor for Parkinson\'s disease (PD), so it is of major interest to understand how it leads to cell dysfunction and death.

Despite the propensity of tau to misfold, it has been difficult to demonstrate the presence of insoluble fibrils of tau in animal and living cell models. Indeed, even in the test tube, fibril formation of pure tau requires addition of polyanionic polymers, such as heparin (Goedert et al., 1996). Many studies of tau have therefore relied on non-neuronal cell models where mutant tau is over-expressed to understand the causes of tau-related cell death. However, not only is the cellular milieu unlikely to be similar to that of neurons, but many cell lines express immortalising genes, making these cells prone to die by apoptosis whereas death by apoptosis in neurodegeneration is rather rare. In most studies, even those involving primary central nervous system (CNS) neurons transfected with tau, cell death is only studied over a few days, unlike the case in human disease where neuronal death extends over decades.

To address this problem, we sought a robust primary neuronal model of tauopathy, leading us to develop a culture system of dorsal root ganglion (DRG) neurons from a transgenic mouse expressing human mutant P301S tau (Mellone et al., 2013). The P301S tau mice develop gradual degeneration in the CNS over 5-6 months that is accompanied by tau hyperphosphorylation, fibril formation with identical structures to those found typically in FTDP-17T with a P301L mutation, and cell death. The advantage of this culture system is that these neurons can be cultured from adult mice at any age, and cultures can be maintained for months, during which time one can study how tau becomes hyperphosphorylated, how it misfolds, how pathology develops and how the neurons die.

However, until recently, we have found it impossible to track which living DRG neurons develop filamentous tau because we lacked a dye that penetrates living neurons and binds to filamentous tau in a reliable and specific manner without toxicity or perturbing cell physiology. The problem arises because less than 20% of the neurons express transgenic tau, and of these less than 50% (so overall around 10%) develop full advanced tau pathology at any one time. Moreover, as some neurons develop tau filaments, others that had already developed filaments will have died. Hence, we could only verify the presence of tau fibrils in fixed cultures, which had been traced after studies on living neurons, by returning to the same field of view, a very laborious process. We tried several dyes on the neurons -- including thioflavin T and S, 2-(4'-Methylaminophenyl) benzothiazole (BTA)-1, and congo red (for structures see [**Figure 1**](#F1){ref-type="fig"}), but either the dyes did not penetrate the neurons (congo red, BTA-1) or the background was too high (Thioflavin T/S), leading to a poor signal to noise ratio.
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In our paper published in *Frontiers in Neuroscience* (Brelstaff et al., 2015), we demonstrate the use of the pentameric form of formyl thiophene acetic acid (pFTAA) as a vital fluorescent dye that stains specifically filamentous tau in living neurons. We use several criteria to demonstrate that pFTAA binds to filamentous tau in the neurons:

1\) Positive staining coincides only with those neurons that express markers of filamentous tau, the anti phospho-T212/S214/T217 antibody AT100 and MC1, a conformational antibody that detects a compacted 'paper-clip' conformation of tau that is found in AD brains with tau pathology. pFTAA+ve neurons were also positive for the hyperphosphorylated epitopes pS202/pT205 (AT8) and pS396/pS404 (PHF-1 or AD2). However, although AT8 is widely used to diagnose NFTs in AD and other tauopathies, and the name PHF-1 implies that the antibody stains paired helical filaments (*e.g*., NFTs), in fact, these antibodies stain both phosphorylated soluble and filamentous tau so cannot be used as sole markers for filaments.

2\) Neurons that stained with pFTAA and MC1 can no longer be stained after treating the cells with formic acid, which solublises filamentous tau by changing its conformation, although they do stain again with an antibody that detects total human P301S tau.

3\) pFTAA did not stain neurons cultured from 2-month-old P301S tau mice, which express as much total P301S tau as that found in more mature neurons, but have marginal, if any filamentous tau, nor did it stain neurons cultured from a 5 month-old transgenic mouse known as Alz17 (Probst et al., 2000), which expresses the longest human tau isoform under the same Thy1.2 promoter as that used to generate P301S tau mice.

We demonstrate the utility of the dye by showing that we can now follow the same set of pFTAA-stained neurons in culture up to 25 days. After scoring for survival we can clearly conclude that DRG neurons expressing pFTAA+ve filamentous tau die faster than neurons that are tau+ve but pFTAA-ve present in the same culture.

The reason that pFTAA performs so well is that it binds tightly to tau filaments, with a half saturation constant (EC~50~) of 142 nM. This likely explains why it can be used to visualise filamentous tau in live neurons, while other dyes give poor signal to noise. The differences in affinity can be seen in [**Figure 2**](#F2){ref-type="fig"}, which compares the binding of pFTAA with that of heptameric FTAA (EC~50~, 600 nM) and Thioflavin T (EC~50~, 3.7 µM).
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In keeping with its high affinity, staining is remarkably stable. We have inspected fixed brains from mice that were injected with pFTAA 6 months prior to observation, and still see a clear pattern of staining (an example shown in Brelstaff et al., 2015).

By distinguishing filament+ve from filament-ve neurons, both of which express tau, we are at last in a position to study the mechanism of neuronal cell death by interfering with critical steps in the process. For example, several reports suggest that autophagy enhancement may benefit neurons expressing toxic proteins such as HD, SOD1, and tau (Frake et al., 2015). There is also an argument as to whether tau aggregates are the toxic species (Kuchibhotla et al., 2014), a question we can now answer using pFTAA. Moreover, we are now in a position to select by FACS three populations of neurons -- pFTAA+ve neurons, pFTAA-ve htau+ve neurons (that have not yet formed filaments), and unlabelled htau-ve neurons, and apply omic techniques to understand the changes wrought by filamentous tau. And lastly, it has not escaped our notice that abundant neurons from P301S tau mice at advanced stages of pathology are also labeled *in vivo* with pFTAA after delivery *via* intravenous injection (Brelstaff et al., 2015). We are now establishing cultures from these brains as deciphering the mechanism of neuronal death in CNS neurons is of prime importance.

Some remarks about the limitation of pFTAA should be heeded. First, the dye stains other filamentous proteins, not least amyloid plaques in human AD brains, and prions that have converted to Prp^SC^ (Aslund et al., 2009). The same is true in mouse models of these diseases. Although the spectral properties of pFTAA bound to these different proteins may be different, it may be difficult to distinguish between beta-amyloid+ve plaques and tau filaments, especially if the latter are released from cells into the brain parenchyma and transmitted to other neurons (Clavaguera et al., 2015). As with all fluorescent compounds, the dye will bleach upon high illumination, although we did not notice any reduction in intensity when exposed to the same cumulative intensity we used to visualize the bound dye every day from day 7 to day 25 in culture.

Altogether, use of pFTAA has solved a major problem in trying to decipher mechanisms of cell death induced by filamentous forms of tau, as we can now follow living neurons to their death. We also noted previously that DRG neurons with abnormal forms of tau regenerate abnormally, with splayed growth cones, spheroids (a typical feature of human tauopathies), and thick short axons, after they are severed prior to culture (Mellone et al., 2013). Given that we can identify pFTAA+ve neurons and axons, we can now approach the question whether tau filaments, or soluble abnormal tau, are responsible for inducing these aberrant retarded growth patterns. This will be especially interesting in studying the regeneration of DRG neurons (and motor neurons, which also express pFTAA+ve filamentous tau (Klingstedt et al., 2013)) *in vivo*, and ultimately CNS neuronal axons and dendrites during synapse formation.
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